These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8193425)

  • 1. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy.
    Spinler SA; Cziraky MJ
    Ann Pharmacother; 1994 Mar; 28(3):343-51. PubMed ID: 8193425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New lipid lowering drugs and new effects of old drugs.
    Dujovne CA
    Curr Opin Lipidol; 1997 Dec; 8(6):362-8. PubMed ID: 9412777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New lipid-lowering agents.
    Wierzbicki AS
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):365-76. PubMed ID: 14661995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
    Tsushima T; Tsushima Y; Sullivan C; Hatipoglu B
    Endocr Pract; 2023 Jun; 29(6):491-497. PubMed ID: 36563785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a)-clinical aspects and future challenges.
    Kurt B; Soufi M; Sattler A; Schaefer JR
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):26-32. PubMed ID: 25732622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease.
    Sano R; Fujino A; Saito T; Takenaka K; Yahata Y; Ogyu A; Toyota T
    Tohoku J Exp Med; 1993 Apr; 169(4):299-307. PubMed ID: 8248919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent effect of niceritrol on plasma lipoprotein-a.
    Teramoto T; Yamada N; Shimano H; Oka Y; Itakura H; Saito Y; Morisaki N; Shirai K; Ishikawa T; Tada N; Ito H; Yamanouchi T; Matsushima T; Kawakami M; Murase T; Okubo M; Totsuka Y; Kikuchi M
    Scand J Clin Lab Invest; 1996 Jul; 56(4):359-65. PubMed ID: 8837243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nicotinic acid and the derivative].
    Ogaki S; Matsushima T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract]   [Full Text] [Related]  

  • 18. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the therapeutic options to lower lipoprotein(a).
    Baragetti A; Da Dalt L; Norata GD
    Eur J Clin Invest; 2024 Sep; 54(9):e14254. PubMed ID: 38778431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.